FDA Grants Orphan Drug Designation to BCMA-targeting Specific T Cell Activating Recombinant Protein (HPN217) for Patients with Multiple Myeloma
The U.S. Food and Drug Administration decided to open the Orphan Drug Designation (ODD) to an investigational drug for the […]